Work

A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2577

Authors: Monica M. Mita, Patricia LoRusso, Grant A. McArthur, Edward S. Kim, Gordon L. Bray, Nanette H Hock, Eric J. Laille, Ida Aronchik, Ellen Filvaroff, Xiaoling Wu, Johanna C. Bendell

Institutions: Cedars-Sinai Medical Center, Yale Cancer Center, Yale University, The University of Melbourne, Peter MacCallum Cancer Centre, Levine Cancer Institute, Celgene (United States), Tennessee Oncology

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2780194508

Cites:

Cited by: 16

Related to: 10